Filtered By:
Specialty: Neurology
Therapy: Immunotherapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 346 results found since Jan 2013.

Emerging Subspecialties in Neurology: Headache medicine
We describe the history of the headache field, recent advances, and information about training and working in the headache field.
Source: Neurology - March 27, 2017 Category: Neurology Authors: Begasse de Dhaem, O., Minen, M. T. Tags: All Headache, Migraine, All Education RESIDENT AND FELLOW SECTION Source Type: research

Autoimmune encephalitis-Challenges and management in intensive medical care
This article outlines the ICU treatment of autoimmune encephalitis and describes the most common challenges and complications of (neuro)intensive medical care and their management.PMID:36651935 | DOI:10.1007/s00115-022-01423-x
Source: Der Nervenarzt - January 18, 2023 Category: Neurology Authors: Dirk Br ämer Christian Geis Albrecht G ünther Source Type: research

New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review
ConclusionThis systematic review suggests that there is an association between NMOSD and SARS-CoV-2 infections and COVID-19 vaccinations. This association requires further study using quantitative epidemiological assessments in a large population to better quantify the risk.
Source: Frontiers in Neurology - June 22, 2023 Category: Neurology Source Type: research

Antibodies to neuronal surface antigens in possible autoimmune encephalitis and new-onset refractory status epilepticus (NORSE) (S21.007)
Conclusions:NSA-abs were detected in 39% of patients with possible AE; 74% of these patients improved. In contrast, patients with NORSE did not have NSA-abs, were refractory to immunotherapies, and more frequently had poor outcome.Disclosure: Dr. Iizuka has received research support from Mitsubishi Tanabe Pharma Corporation. Dr. Kaneko has nothing to disclose. Dr. Tominaga has nothing to disclose. Dr. Kanazawa has nothing to disclose. Dr. Ugawa has received personal compensation for activities with CHUGAI-IGAKUSHA, Igaku-Shoin Ltd, Medical View Co. Ltd., and Blackwell Publishing K.K. Dr. Ugawa has received research support...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Iizuka, T., Kaneko, J., Tominaga, N., Kanazawa, N., Nonoda, Y., Hara, A., Onozawa, Y., Asari, H., Hata, T., Kaneko, J., Yoshida, K., Sugiura, Y., Ugawa, Y., Watanabe, M., Tomita, H., Kosakai, A., Kaneko, A., Ishima, D., Kitamura, E., Dalmau, J., Nishiyama Tags: Epilepsy and Clinical Neurophysiology (EEG) I Source Type: research

Autoimmune Epilepsy: The Evolving Science of Neural Autoimmunity and Its Impact on Epilepsy Management
Semin Neurol 2018; 38: 290-302 DOI: 10.1055/s-0038-1660860Autoimmune epilepsy is increasingly recognized as a distinct clinical entity, driven in large part by the recent discovery of neural autoantibodies in patients with isolated or predominant epilepsy presentations. Detection of neural autoantibodies in high-risk epilepsy patients supports an immune-mediated cause of seizures and, if applicable, directs the search for an underlying cancer when the paraneoplastic association of the associated antibody is compelling. Early diagnosis of autoimmune epilepsy is crucial, as prompt initiation of immunosuppressive treatment in...
Source: Seminars in Neurology - July 16, 2018 Category: Neurology Authors: Quek, Amy M.L. O'Toole, Orna Tags: Review Article Source Type: research

Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis
Conclusion We have demonstrated the validity of standardizing the T1w/T2w ratio in an MS cohort. The sT1w/T2w ratio reduces CoV in NAWM of both MS patients and HC and was the only investigated measure to detect differences in NAWM in MS compared to HC. We propose that the sT1w/T2w ratio is a reliable and sensitive measure that can be used to investigate NAWM changes in MS. Author Contributions GC, MS, CF, and FP contributed to the conception and design of the study. MS, JB-S, KR, and SA were involved in the acquisition and organization of clinical and/or MRI data. GC performed the statistical analysis and wrote the firs...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimers disease (P1.099)
Conclusions:The magnitude of NPS in preclinical cases is linked to transitory metabolic dysfunctions within limbic networks vulnerable to the AD and predicts subsequent PCC hypometabolism. These findings support an emerging conceptual framework, in which NPS constitute an early clinical manifestation of AD pathophysiology.Study Supported by:This work was supported by the Canadian Institutes of Health Research (CIHR) [MOP-11-51-31], Canadian Consortium of Neurodegeneration in Aging (CIHR-CCNA), the Weston Brain Institute and the Alzheimer’s Association [NIRG-08-92090]. Pedro Rosa-Neto is supported by the Fonds de la r...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Ng, K. P., Pascoal, T. A., Mathotaarachchi, S., Chung, C.-O., Benedet, A. L., Shin, M., Kang, M. S., Li, X., Ba, M., Kandiah, N., Rosa-Neto, P., Gauthier, S. Tags: Aging and Dementia: Biomarkers Source Type: research

Positive Response to Alemtuzumab (ALE) Rescue Immunotherapy in a High Disability, Treatment-Refractory Multiple Sclerosis (MS) Cohort (P7.224)
CONCLUSIONS: This patient profile differs greatly from prior trials in the cohort disability, relapse frequency, treatment experience, as well as the qualitative ALE responses in ARR. However, our cohort manifests greater disability improvement than previously reported for disabled and progressive patients, despite lack of suppression of relapses following ALE immunotherapy. Generally this patient profile has improved disability after ALE despite continuing clinical disease activity. Aggressive, rescue immunotherapy should be further studied in this challenging clinical patient profile.Study Supported by: Genzyme-Sanofi vi...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Hunter, S., Hunter, H., Kantor, D. Tags: Multiple Sclerosis and CNS Inflammatory Diseases: Treatment Source Type: research

The promises of immunotherapy in gliomas
Purpose of review: Also owing to the limited efficacy of targeted therapies, there has been a renewed interest in targeting gliomas with immunotherapy. But despite considerable efforts using sophisticated approaches, proof of efficacy beyond case studies is still lacking. The purpose of this review is to summarize and discuss current immunotherapeutic approaches and efforts to understand mechanisms of response and resistance. Recent findings: The recent failure of large randomized clinical trials using targeted vaccines and checkpoint inhibitors to improve clinical outcome have underlined the grand challenges in this ther...
Source: Current Opinion in Neurology - November 2, 2017 Category: Neurology Tags: NEOPLASMS: Edited by Jean-Yves Delattre Source Type: research

Treatment of antibody-mediated encephalomyelitis : Strategies for the treatment of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease
CONCLUSION: Treatment of antibody-mediated encephalomyelitis differs from treatment of multiple sclerosis and requires specific measures.PMID:33783551 | DOI:10.1007/s00115-021-01090-4
Source: Der Nervenarzt - March 30, 2021 Category: Neurology Authors: Ilya Ayzenberg Ingo Kleiter Source Type: research

Paraneoplastic neurological syndromes: a practical approach to diagnosis and management
Pract Neurol. 2021 Sep 11:practneurol-2021-003073. doi: 10.1136/practneurol-2021-003073. Online ahead of print.ABSTRACTParaneoplastic neurological syndromes (PNS) are the immune-mediated effects of a remote cancer and are characterised by an autoantibody response against antigens expressed by the tumour. Classically, well-characterised 'onconeuronal' antibodies target intracellular antigens and hence cannot access their antigens across intact cell membranes. The pathogenic mediators are likely to be neuronal-specific T cells. There is a variable response to immunotherapies and the clinical syndrome helps to direct the sear...
Source: Practical Neurology - September 12, 2021 Category: Neurology Authors: Sophie Binks Christopher Uy Jerome Honnorat Sarosh R Irani Source Type: research